Prospective karyotype analysis in adult acute lymphoblastic leukemia: The cancer and leukemia group B experience

Blood

Volumn 93, Issue 11, 1999, Pages 3983-3993

  Wetzler, Meir ^a   Dodge, Richard K ^b   Mrózek, Krzysztof ^b   Carroll, Andrew J ^b   Tantravahi, Ramana ^b   Block, AnneMarie W ^b   Pettenati, Mark J ^b   Le Beau, Michelle M ^b   Frankel, Stanley R ^b   Stewart, Carleton C ^b   Szatrowski, Ted P ^b   Schiffer, Charles A ^b   Larson, Richard A ^b   Bloomfield, Clara D ^b  

^a ROSWELL PARK CANCER INSTITUTE   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT;

ACUTE LYMPHOBLASTIC LEUKEMIA; ADOLESCENT; ADULT; AGED; ARTICLE; BONE MARROW TRANSPLANTATION; CANCER COMBINATION CHEMOTHERAPY; CANCER SURVIVAL; CHROMOSOME TRANSLOCATION; CONTROLLED STUDY; DIAGNOSTIC VALUE; FEMALE; HUMAN; HUMAN CELL; KARYOTYPING; LEUKEMIA REMISSION; MAJOR CLINICAL STUDY; MALE; PREDICTION; PRIORITY JOURNAL; PROGNOSIS; TREATMENT OUTCOME;

ADOLESCENT; ADULT; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CHROMOSOME ABERRATIONS; CHROMOSOME DISORDERS; DISEASE-FREE SURVIVAL; GENETIC MARKERS; HUMANS; KARYOTYPING; LEUKEMIA, LYMPHOCYTIC, ACUTE; MULTIVARIATE ANALYSIS; PROGNOSIS; PROSPECTIVE STUDIES; RISK FACTORS; SURVIVAL ANALYSIS;

EID: 0033153105     PISSN: 00064971     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (34)

1. Faderl S, Kantarjian HM, Talpaz M, Estrov Z: Clinical significance of cytogenetic abnormalities in adult acute lymphoblastic leukemia. Blood 91:3995, 1998
2. Copelan EA, McGuire EA: The biology and treatment of acute lymphoblastic leukemia in adults. Blood 85:1151, 1995
3. Ellison RR, Mick R, Cuttner J, Schiffer CA, Silver RT, Henderson ES, Woliver T, Royston I, Davey FR, Glicksman AS, Bloomfield CD, Holland JF: The effects of postinduction intensification treatment with cytarabine and daunorubicin in adult acute lymphocytic leukemia: A prospective randomized clinical trial by Cancer and Leukemia Group B. J Clin Oncol 9:2002, 1991
4. Cuttner J, Mick R, Budman DR, Mayer RJ, Lee EJ, Henderson ES, Weiss RB, Paciucci PA, Sobol R, Davey F, Bloomfield CD, Schiffer CA: Phase III trial of brief intensive treatment of adult acute lymphocytic leukemia comparing daunorubicin and mitoxantrone: A CALGB Study. Leukemia 5:425, 1991
5. Larson RA, Dodge RK, Burns CP, Lee EJ, Stone RM, Schulman P, Duggan D, Davey FR, Sobol RE, Frankel SR, Hooberman AL, Westbrook CA, Arthur DC, George SL, Bloomfield CD, Schiffer CA: A five-drug remission induction regimen with intensive consolidation for adults with acute lymphoblastic leukemia: Cancer and Leukemia Group B Study 8811. Blood 85:2025, 1995
6. Larson RA, Dodge RK, Linker CA, Stone RM, Powell BL, Lee EJ, Schulman P, Davey FR, Frankel SR, Bloomfield CD, George SL, Schiffer CA: A randomized controlled trial of filgrastim during remission induction and consolidation chemotherapy for adults with acute lymphoblastic leukemia: CALGB Study 9111. Blood 92:1556, 1998
7. Szatrowski TP, Larson RA, George S, Dodge R, Hurd D, Kolitz J, Velez-Garcia E, Sklar J, Reynolds C, Westbrook CA, Frankel SR, Stewart C, Bloomfield CD, Schiffer CA: Anti-B4-blocked ricin as consolidation therapy for patients with B-lineage acute lymphoblastic leukemia (ALL): A phase II trial (CALGB 9311). Blood 86:783a, 1995 (abstr, suppl 1)
8. Bennett JM, Catovsky D, Daniel MT, Flandrin G, Galton DA, Gralnick HR, Sultan C: The morphological classification of acute lymphoblastic leukaemia: Concordance among observers and clinical correlations. Br J Haematol 47:553, 1981
9. Catovsky D, Matutes E, Buccheri V, Shetty V, Hanslip J, Yoshida N, Morilla R: A classification of acute leukaemia for the 1990s. Ann Hematol 62:16, 1991
10. Mitelman F (ed): ISCN (1995): An International System for Human Cytogenetic Nomenclature. Basel, Switzerland, Karger, 1995
11. Sobol RE, Mick R, Royston I, Davey FR, Ellison RR, Newman R, Cuttner J, Griffin JD, Collins H, Nelson DA, Bloomfield CD: Clinical importance of myeloid antigen expression in adult acute lymphoblastic leukemia. N Engl J Med 316:1111, 1987
12. Stewart CC: Clinical applications of flow cytometry. Immunologic methods for measuring cell membrane and cytoplasmic antigens. Cancer 69:1543, 1992
13. Cox DR: Regression models and life tables. J R Stat Soc 34:187, 1972
14. Kaplan EL, Meier P: Nonparametric estimation from incomplete observations. J Am Stat Assoc 53:457, 1958
15. Simon R, Lee YJ: Nonparametric confidence limits for survival probabilities and median survival time. Cancer Treat Rep 66:37, 1982
16. Peto R, Pike MC, Armitage P, Breslow NE, Cox DR, Howard SV, Mantel N, McPherson K, Peto J, Smith PG: Design and analysis of randomized clinical trials requiring prolonged observation of each patient. II. Analysis and examples. Br J Cancer 35:1, 1977
17. Bloomfield CD, Secker-Walker LM, Goldman AI, Van Den Berghe H, de la Chapelle A, Ruutu T, Alimena G, Garson OM, Golomb HM, Rowley JD, Kaneko Y, Whang-Peng J, Prigogina E, Philip P, Sandberg AA, Lawler SD, Mitelman F: Six-year follow-up of the clinical significance of karyotype in acute lymphoblastic leukemia. Cancer Genet Cytogenet 40:171, 1989
18. The Groupe Francais de Cytogenetique Hematologique: Cytogenetic abnormalities in adult acute lymphoblastic leukemia: Correlations with hematologic findings and outcome. A collaborative study of the Groupe Francais de Cytogenetique Hematologique. Blood 87:3135, 1996
19. Secker-Walker LM, Prentice HG, Durrant J, Richards S, Hall E, Harrison G, on behalf of the MRC Adult Leukaemia Working Party: Cytogenetics adds independent prognostic information in adults with acute lymphoblastic leukaemia on MRC trial UKALL XA. Br J Haematol 96:601, 1997
20. Bloomfield CD, Peterson LC, Yunis JJ, Brunning RD: The Philadelphia chromosome (Ph1) in adults presenting with acute leukaemia: A comparison of Ph1+ and Ph1-patients. Br J Haematol 36:347, 1977
21. Gaynor J, Chapman D, Little C, McKenzie S, Miller W, Andreeff M, Arlin Z, Berman E, Kempin S, Gee T, Clarkson B: A cause-specific hazard rate analysis of prognostic factors among 199 adults with acute lymphoblastic leukemia: The Memorial Hospital experience since 1969. J Clin Oncol 6:1014, 1988
22. Kantarjian HM, Walters RS, Keating MJ, Smith TL, O'Brien S, Estey EH, Huh YO, Spinolo J, Dicke K, Barlogie B, McCredie KB, Freireich E: Results of the vincristine, doxorubicin, and dexamethasone regimen in adults with standard- and high-risk acute lymphocytic leukemia. J Clin Oncol 8:994, 1990
23. Linker CA, Levitt LJ, O'Donnell M, Forman SJ, Ries CA: Treatment of adult acute lymphoblastic leukemia with intensive cyclical chemotherapy: A follow-up report. Blood 78:2814, 1991
24. Pui CH: Acute leukemias with the t(4;11)(q21;q23). Leuk Lymphoma 7:173, 1992
25. Stockschlader M, Hegewisch-Becker S, Kruger W, tom Dieck A, Mross K, Hoffknecht M, Berger C, Kohlschutter B, Martin H, Peters S, Kabisch H, Kuse R, Weh H, Zander A: Bone marrow transplantation for Philadelphia-chromosome-positive acute lymphoblastic leukemia. Bone Marrow Transplant 16:663, 1995
26. Chao NJ, Blume KG, Forman SJ, Snyder DS: Long-term follow-up of allogeneic bone marrow recipients for Philadelphia chromosome-positive acute lymphoblastic leukemia. Blood 85:3353, 1995
27. Deconinck E, Cahn JY, Milpied N, Jouet JP, Vernant JP, Esperou H, Lioure B, Bordigoni P, Leblond V, Troussard X, Caillot D, Cordonnier JM, Herve P: Allogeneic bone marrow transplantation for high-risk acute lymphoblastic leukemia in first remission: Long-term results for 42 patients conditioned with an intensified regimen (TBI, high-dose Ara-C and melphalan). Bone Marrow Transplant 20:731, 1997
28. Dunlop LC, Powles R, Singhal S, Treleaven JG, Swansbury GJ, Meller S, Pinkerton CR, Horton C, Mehta J: Bone marrow transplantation for Philadelphia chromosome-positive acute lymphoblastic leukemia. Bone Marrow Transplant 17:365, 1996
29. Okabe M, Kuni-eda Y, Sugiwura T, Tanaka M, Miyagishima T, Saiki I, Minagawa T, Kurosawa M, Itaya T, Miyazaki T: Inhibitory effect of interleukin-4 on the in vitro growth of Ph1-positive acute lymphoblastic leukemia cells. Blood 78:1574, 1991
30. Carroll M, Ohno-Jones S, Tamura S, Buchdunger E, Zimmermann J, Lydon NB, Gilliland DG, Druker BJ: CGP 57148, a tyrosine kinase inhibitor, inhibits the growth of cells expressing BCR-ABL, TEL-ABL, and TEL-PDGFR fusion proteins. Blood 90:4947, 1997
31. Snyder DS, Wu Y, Wang JL, Rossi JJ, Swiderski P, Kaplan BE, Forman SJ: Ribozyme-mediated inhibition of bcr-abl gene expression in a Philadelphia chromosome-positive cell line. Blood 82:600, 1993
32. Martial P, Lewalle P, Taj AS, Philippe M, Larondelle Y, Vaerman JL, Wildmann C, Goldman JM, Michaux JL: Retrovirally transduced antisense sequences stably suppress P210BCR-ABL expression and inhibit the proliferation of BCR/ABL-containing cell lines. Blood 81:502, 1993
33. Chucrallah AE, Stass SA, Huh YO, Albitar M, Kantarjian HM: Adult acute lymphoblastic leukemia at relapse. Cytogenetic, immunophenotypic, and molecular changes. Cancer 76:985, 1995
34. Secker-Walker LM, Alimena G, Bloomfield CD, Kaneko Y, Whang-Peng J, Arthur DC, de la Chapelle A, Reeves BR, Rowley JD, Lawler SD, Mitelman F: Cytogenetic studies of 21 patients with acute lymphoblastic leukemia in relapse. Cancer Genet Cytogenet 40:163, 1989